Celebrex Warning Pains Pfizer
Updated from 1:10 p.m. EST
Pfizer (PFE) shares plunged in frenetic trading volume Friday after the drugmaker said new data from cancer trials showed its arthritis drug Celebrex posed "increased cardiovascular risk" when used in high doses.
Celebrex is a COX-2 inhibitor drug like Merck's (MRK) Vioxx, which that drugmaker withdrew from the market in late September because of similar health and safety concerns.
Pfizer said it received new information last night about two long-term cancer trials concerning the cardiovascular safety of Celebrex. The other one "revealed no greater cardiovascular risk than placebo."Celebrex is approved for use in the U.S. for the treatment of arthritis and pain. Pfizer has stood by the safety of its use since the Vioxx recall, which has knocked some 40% off Merck shares, and repeated that it had no plans to pull the money-spinning drug from the market. The Food and Drug Administration, however, responded to the development by recommending that physicians advise patients to use the lowest dose possible. Shares of Pfizer hit a new 52-week low of $25.76, down $3.22, or 11.1%. Shares fell as low as $23.52. About 277 million shares had already changed hands -- about nine times the average daily volume of about 31 million shares. Pfizer stressed the importance of "placing this new information in context," because the trial results differ from "the large body of data that we and others have accumulated over time, in which an increased risk of serious cardiovascular events in arthritis patients, even at higher-than-recommended doses, had not been seen." "These clinical trial results are new. The cardiovascular findings in one of the studies (APC) are unexpected and not consistent with the reported findings in the second study," the company said in a statement. "Pfizer is taking immediate steps to fully understand the results and rapidly communicate new information to regulators, physicians and patients around the world."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV